TipRanks
PharmaCyte Biotech (DE:EFYA)
STUTTGART:EFYA
Germany Market

PharmaCyte Biotech (EFYA) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

EFYA Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
PharmaCyte
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EFYA Stock 12 Month Forecast

There Are No Analyst Ratings for DE:EFYA In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

EFYA Financial Forecast

EFYA Earnings Forecast

Next quarter’s earnings estimate for EFYA is -€0.04 with a range of -€0.04 to -€0.04. The previous quarter’s EPS was -€0.05. EFYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year EFYA has its overall industry.
Next quarter’s earnings estimate for EFYA is -€0.04 with a range of -€0.04 to -€0.04. The previous quarter’s EPS was -€0.05. EFYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year EFYA has its overall industry.
No data currently available

EFYA Sales Forecast

Next quarter’s sales forecast for EFYA is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. EFYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year EFYA has its overall industry.
Next quarter’s sales forecast for EFYA is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. EFYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year EFYA has its overall industry.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
ZYMEZymeworks
TEVATeva Pharmaceutical
AHCOAdaptHealth
PTGXProtagonist Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

EFYA Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
0
0
In the current month, EFYA has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. EFYA average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

EFYA Stock Forecast FAQ

What is DE:EFYA’s average 12-month price target, according to analysts?
Currently, no data Available
What is DE:EFYA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:EFYA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is PharmaCyte Biotech a Buy, Sell or Hold?
      Currently, no data Available
      What is PharmaCyte Biotech’s share price target?
      Currently, no data Available
      What do analysts say about PharmaCyte Biotech?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of PharmaCyte Biotech?
      To buy shares of DE:EFYA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.